AstraZeneca’s Capivasertib combined with fulvestrant reduces the risk of disease progression or death by 40%, compared with placebo plus fulvestrant, in patients with HR-positive advanced breast cancer, according to results from the Phase III ‘CAPItello-291’ study, presented at the 2022 San Antonio Symposium on Breast Cancer (SABCS).
“Capivasertib represents a major advance in an area with therapeutic gaps, demonstrating its efficacy in patients with HR-positive, HER2-low or negative advanced breast cancer. We believe that these findings, which showed benefits in both the overall population and those with altered AKT pathway biomarker positive, may reshape the treatment of HR-positive breast cancer. Capivasertib could become a new option for these patients,” said Susan Galbraith, executive vice president of oncology research and development at AstraZeneca.
The study observed a statistically and clinically significant improvement in progression-free survival (PFS) in patients with locally advanced or metastatic breast cancer, with hormone receptor (HR) positive, HER2 low or negative, after recurrence or progression during or after therapy. endocrine (with or without CDK4/6 inhibitor).
In the population with impaired AKT pathway biomarker, the combination reduced the risk of disease progression or death by 50% compared with placebo plus fulvestrant. Abnormalities of the AKT pathway are common in breast cancer and affect up to 50% of patients with HR-positive advanced breast cancer.
Abnormalities of the AKT pathway are common in breast cancer and affect up to 50% of patients with HR-positive advanced breast cancer.
“These data demonstrate the potential for capivasertib to be a game changer as a new treatment option for patients with HR-positive advanced breast cancer. Additionally, this potentially first-of-its-kind treatment has been shown to delay disease progression in patients who have progressed or become resistant to endocrine therapies and CDK4/6 inhibitors,” said the paper’s principal investigator, Nicholas Turner.
Read the complete news (isanidad)
